Skip to main content
. Author manuscript; available in PMC: 2014 Feb 17.
Published in final edited form as: Breast Cancer Res Treat. 2010 Jun 11;127(1):81–89. doi: 10.1007/s10549-010-0975-z

Fig. 1.

Fig. 1

ME1 is specific for HLA-B7. ME1 was harvested from HB-119 hybridoma culture supernatants. ME1 specificity was tested using HLA B7+ and HLA-B7− PBMCs from three healthy donors in each group by flow cytometry. a and c is a representative plot derived from one healthy individual in each group demonstrating specific binding of ME1 (gray filled plots) to HLA-B7+ PBMC obtained (a) but not against HLA-B7− PBMC (c). A panspecific anti-HLA class I binding Ab, W6/32 (gray filled plots), was used as a positive control (b, d). Isotype control Abs to W6/32 (C1.18.4) and ME1 (MOPC-21) (open plots) gave negative results as expected. e Indicates the mean fluorescence shift obtained with W6/32 and ME1 mAbs against HLA-B7+ (n = 3) and HLA-B7 − (n = 3) PBMCs